- Home
- TCRX vs NTIC Comparison
TCRX vs NTIC Comparison
Compare TCRX & NTIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRX
- NTIC
- Stock Information
- Founded
- TCRX 2018
- NTIC 1970
- Country
- TCRX United States
- NTIC United States
- Employees
- TCRX N/A
- NTIC N/A
- Industry
- TCRX Biotechnology: Pharmaceutical Preparations
- NTIC Industrial Specialties
- Sector
- TCRX Health Care
- NTIC Industrials
- Exchange
- TCRX Nasdaq
- NTIC Nasdaq
- Market Cap
- TCRX 82.1M
- NTIC 77.8M
- IPO Year
- TCRX 2021
- NTIC N/A
- Fundamental
- Price
- TCRX $1.93
- NTIC $7.94
- Analyst Decision
- TCRX Strong Buy
- NTIC
- Analyst Count
- TCRX 6
- NTIC 0
- Target Price
- TCRX $9.50
- NTIC N/A
- AVG Volume (30 Days)
- TCRX 572.1K
- NTIC 79.7K
- Earning Date
- TCRX 08-11-2025
- NTIC 07-10-2025
- Dividend Yield
- TCRX N/A
- NTIC 0.51%
- EPS Growth
- TCRX N/A
- NTIC N/A
- EPS
- TCRX N/A
- NTIC 0.31
- Revenue
- TCRX $4,421,000.00
- NTIC $85,268,129.00
- Revenue This Year
- TCRX $159.20
- NTIC $2.05
- Revenue Next Year
- TCRX N/A
- NTIC $4.70
- P/E Ratio
- TCRX N/A
- NTIC $25.30
- Revenue Growth
- TCRX N/A
- NTIC 3.46
- 52 Week Low
- TCRX $1.02
- NTIC $6.75
- 52 Week High
- TCRX $7.44
- NTIC $15.09
- Technical
- Relative Strength Index (RSI)
- TCRX 63.03
- NTIC 49.34
- Support Level
- TCRX $1.75
- NTIC $7.88
- Resistance Level
- TCRX $1.96
- NTIC $8.49
- Average True Range (ATR)
- TCRX 0.14
- NTIC 0.39
- MACD
- TCRX 0.01
- NTIC -0.05
- Stochastic Oscillator
- TCRX 94.00
- NTIC 24.26
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About NTIC Northern Technologies International Corporation
Northern Technologies International Corp, or NTIC is a United States-based firm that develops and markets environmentally beneficial products and services world-wide either directly or through a network of joint ventures, distributors, and agents. It operates through two segments which include ZERUST products and services and Nature-Tec products. Its main business is providing corrosion prevention solutions that are marketed under the ZERUST brand. The company also sells a portfolio of bio-based and biodegradable (compostable) polymer resin compounds and finished products marketed under the Nature-Tec brand. The ZERUST brand generates a vast majority of the revenue for the company.